1 min read
Chief Medical Officer Summit -CMO 360°
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
2 min read
In the intricate world of pharmaceuticals and biotechnology, every step of drug development is meticulously scrutinized by regulatory bodies. For small to medium-sized companies in the field, the journey can be fraught with challenges, especially in biologics development. In this case study, we delve into how Veristat helped a small-sized biotech company overcome a partial clinical hold and smoothly steer multiple products through development.
Our story starts with a promising biotechnology company working on the mid-clinical development of a novel cell therapy/immunotherapy product platform to treat various types of cancer. However, their journey took an unexpected turn when one of their products was subjected to a partial clinical hold due to critical CMC deficiencies. This partial clinical hold had far-reaching consequences and led to multiple information requests from the FDA for all products within the platform.
Facing this challenge, the biotech company turned to Veristat for guidance and support.
Veristat's regulatory CMC experts provided tailored support to the sponsor, playing a pivotal role in turning the tide.
Thanks to Veristat's unwavering support and expertise, the biotech company was able to move forward from the partial clinical hold. The meticulous attention to detail in the manufacturing and analytical programs ensured that all products across the platform progressed through development without encountering any further clinical delays.
This case study highlights several crucial lessons for companies venturing into the development of biologics:
Navigating the path from concept to approval in the pharmaceutical and biotech industries can be a daunting challenge. However, with the right expertise and strategic guidance, small to medium-sized businesses can overcome these complexities and succeed.
Veristat played a crucial role in helping our sponsor overcome a partial clinical hold and successfully steer multiple products through development. This is a testament to the importance of regulatory CMC expertise and strategic planning in biologics. If you're in the pharmaceutical or biotech industry, this case study is a valuable resource for understanding the nuances of regulatory challenges and how to overcome them.
Download it today and take a step closer to your own success story in biopharmaceutical development.
Learn more
1 min read
Apr 9, 2024 Veristat Events
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
4 min read
Mar 22, 2024 Veristat Events
Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...